NCT00174447

Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

Open Extension Study Evaluating The Long Term Efficacy , Safety And Tolerability Of Oral Ziprasidone In The Treatment Of Patients Who Have Successfully Completed The Previous Ziprasidone Study A1281031

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Ziprasidone	Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid

Timeline

• Start date: 2001-10-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2005-09-15
• Last updated: 2021-03-24
• Results posted: 2009-11-17

Locations

14 sites across 1 country: France